{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:06:57Z","timestamp":1787843217170,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.amjmed.2025.03.020","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T15:55:06Z","timestamp":1743350106000},"page":"1185-1196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Aspirin for Venous Thromboembolism Prophylaxis in Hip Fracture, Total Knee, and Hip Arthroplasty"],"prefix":"10.1016","volume":"138","author":[{"given":"Hannah","family":"Leyva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scimeca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnood","family":"Bikdeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Piazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6450-0448","authenticated-orcid":false,"given":"Samuel Z.","family":"Goldhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.amjmed.2025.03.020_bib0001","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3899\/jrheum.170990","article-title":"Rates of total joint replacement in the United States: Future projections to 2020-2040 using the National Inpatient Sample","volume":"46","author":"Singh","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0002","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.artd.2022.01.020","article-title":"Highlights of the 2021 American Joint Replacement Registry Annual Report","volume":"13","author":"Siddiqi","year":"2022","journal-title":"Arthroplast Today"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/2151459320929581","article-title":"Hip fracture trends in America between 2009 and 2016","volume":"11","author":"Remily","year":"2020","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"8S1","key":"10.1016\/j.amjmed.2025.03.020_bib0004","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/j.arth.2024.01.050","article-title":"Trends in deep vein thrombosis prophylaxis after total knee arthroplasty: 2016 to 2021","volume":"39","author":"Dubin","year":"2024","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jor.2023.11.030","article-title":"Trends in deep vein thrombosis prophylaxis after total hip arthroplasty: 2016 to 2021","volume":"48","author":"Moore","year":"2024","journal-title":"J Orthop"},{"issue":"9","key":"10.1016\/j.amjmed.2025.03.020_bib0006","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1302\/0301-620X.106B9.BJJ-2023-1252.R2","article-title":"Efficacy and safety of commonly used thromboprophylaxis agents following hip and knee arthroplasty","volume":"106-B","author":"Cheok","year":"2024","journal-title":"Bone Joint J"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0007","unstructured":"Hikma Pharmaceuticals USA Inc. Heparin sodium package insert. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/017037Orig1s187lbl.pdf. Accessed March 13, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0008","unstructured":"Sanofi-aventis U.S. LLC. Enoxaparin sodium package insert. Available at: https:\/\/products.sanofi.us\/lovenox\/lovenox.pdf. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0009","unstructured":"GlaxoSmithKline. Fondaparinux sodium package insert. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021345s010lbl.pdf. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0010","unstructured":"Pfizer. Dalteparin package insert. Available at: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=15035. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0011","unstructured":"Upsher-Smith Laboratories, LLC. Jantoven package insert.https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=19a69a72-ac5d-45d5-a94d-a5aaecbe4730&type=display. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0012","unstructured":"Bristol Myers Squibb. Eliquis (apixaban) package insert. Available at: https:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0013","unstructured":"Daiichi Sankyo Inc. Savaysa (edoxaban) package insert. Available at:https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0014","unstructured":"Janssen Pharmaceuticals Inc. Xarelto (rivaroxaban) package insert. Available at:https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf. Accessed March 11, 2025."},{"key":"10.1016\/j.amjmed.2025.03.020_bib0015","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (dabigatran) package insert. Available at: https:\/\/patient.boehringer-ingelheim.com\/us\/pradaxa\/bipdf\/prescribing-information. Accessed March 11, 2025."},{"issue":"4","key":"10.1016\/j.amjmed.2025.03.020_bib0016","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/17453674.2016.1195662","article-title":"Temporal trends in the use of antithrombotics at admission","volume":"87","author":"Madsen","year":"2016","journal-title":"Acta Orthop"},{"issue":"suppl 3","key":"10.1016\/j.amjmed.2025.03.020_bib0017","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/BOT.0000000000001939","article-title":"Venous thromboembolism in hip fracture patients: a subanalysis of the FAITH and HEALTH trials","volume":"34","author":"MacDonald","year":"2020","journal-title":"J Orthop Trauma"},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0018","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.injury.2021.11.052","article-title":"Equivalence of DOACS and LMWH for thromboprophylaxis after hip fracture surgery: systematic review and meta-analysis","volume":"53","author":"Nederpelt","year":"2022","journal-title":"Injury"},{"issue":"12","key":"10.1016\/j.amjmed.2025.03.020_bib0019","doi-asserted-by":"crossref","first-page":"777","DOI":"10.5435\/00124635-201112000-00008","article-title":"AAOS clinical practice guideline: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty","volume":"19","author":"Mont","year":"2011","journal-title":"J Am Acad Orthop Surg"},{"issue":"2 suppl","key":"10.1016\/j.amjmed.2025.03.020_bib0020","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"issue":"x","key":"10.1016\/j.amjmed.2025.03.020_bib0021","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0022","unstructured":"National Institute for Health and Care Excellence (NICE). Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. NICE clinical guideline. Available at:https:\/\/www.nice.org.uk\/guidance\/ng89\/chapter\/Recommendations#interventions-for-people-having-orthopaedic-surgery. Accessed March 11, 2025."},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0023","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jscs.2010.04.010","article-title":"Medicinal potential of willow: a chemical perspective of aspirin discovery","volume":"14","author":"Mahdi","year":"2010","journal-title":"J Saudi Chem Soc"},{"issue":"7","key":"10.1016\/j.amjmed.2025.03.020_bib0024","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"issue":"5-6","key":"10.1016\/j.amjmed.2025.03.020_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane","year":"2003","journal-title":"Thromb Res"},{"issue":"11","key":"10.1016\/j.amjmed.2025.03.020_bib0026","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/jth.12728","article-title":"Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid","volume":"12","author":"Undas","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"8","key":"10.1016\/j.amjmed.2025.03.020_bib0027","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC Review Topic of the Week","volume":"81","author":"Harrington","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2025.03.020_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC Review Topic of the Week","volume":"78","author":"Hsu","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9212","key":"10.1016\/j.amjmed.2025.03.020_bib0029","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0140-6736(00)02110-3","article-title":"Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.amjmed.2025.03.020_bib0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee rrthroplasty","volume":"378","author":"Anderson","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amjmed.2025.03.020_bib0031","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/jama.2022.13416","article-title":"Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: the CRISTAL Randomized Trial","volume":"328","author":"Sidhu","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0032","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2205973","article-title":"Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture","volume":"388","author":"O'Toole","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060000","article-title":"Randomised comparative effectiveness trial of Pulmonary Embolism Prevention after hiP and kneE Replacement (PEPPER): the PEPPER trial protocol","volume":"12","author":"Pellegrini","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0034","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2024-0050","article-title":"The impact of a patient advisory board on a clinical comparative effectiveness trial: a comparison of patient and researcher perspectives","volume":"14","author":"Kernan","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"25","key":"10.1016\/j.amjmed.2025.03.020_bib0035","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","article-title":"What Is the future of Factor XI inhibitors?","volume":"146","author":"Weitz","year":"2022","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.amjmed.2025.03.020_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-024-00352-x","article-title":"Factor XI Inhibitors: a new horizon in anticoagulation therapy","volume":"13","author":"Presume","year":"2024","journal-title":"Cardiol Ther"},{"issue":"1","key":"10.1016\/j.amjmed.2025.03.020_bib0037","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1358863X231206778","article-title":"Factor XI\/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review","volume":"29","author":"Prakash","year":"2024","journal-title":"Vasc Med"},{"issue":"7","key":"10.1016\/j.amjmed.2025.03.020_bib0038","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/ATVBAHA.116.306925","article-title":"Factor XI as a therapeutic target","volume":"36","author":"Gailani","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjmed.2025.03.020_bib0039","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/VHRM.S331614","article-title":"Factor XI inhibition for the prevention of venous thromboembolism: an update on current evidence and future perspectives","volume":"18","author":"Poenou","year":"2022","journal-title":"Vasc Health Risk Manag"},{"issue":"3","key":"10.1016\/j.amjmed.2025.03.020_bib0040","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325001974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934325001974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:30:54Z","timestamp":1762079454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934325001974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0002934325001974"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.03.020","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin for Venous Thromboembolism Prophylaxis in Hip Fracture, Total Knee, and Hip Arthroplasty","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2025.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}